Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.18 EUR
Change Today +0.001 / 0.55%
Volume 377.2K
BTH1V On Other Exchanges
As of 12:30 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

biotie therapies oyj (BTH1V) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/14 - €0.25
52 Week Low
03/10/15 - €0.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOTIE THERAPIES OYJ (BTH1V)

Related News

No related news articles were found.

biotie therapies oyj (BTH1V) Related Businessweek News

No Related Businessweek News Found

biotie therapies oyj (BTH1V) Details

Biotie Therapies Corp. operates as a drug development company. It focuses on the development of drugs for neurodegenerative and psychiatric disorders. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease that is in Phase III development; NRL-1 a proprietary intranasal formulation of diazepam for the treatment of epilepsy; Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which is in Phase II trial. The company’s products also comprise BTT-1023 a monoclonal antibody for treatment of inflammatory diseases focusing on conducting Phase 2 clinical trial; and SYN120 an oral, potent, dual antagonist of the 5-HT6 and 5HT2a receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose. The company has strategic collaboration with UCB Pharma S.A. Biotie Therapies Corp. is based in Turku, Finland.

38 Employees
Last Reported Date: 03/9/15

biotie therapies oyj (BTH1V) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biotie therapies oyj (BTH1V) Key Developments

Biotie Therapies Corp. Reports Consolidated and Parent Earnings Results for the Full Year Ended December 31, 2014

Biotie Therapies Corp. reported consolidated and parent earnings results for the full year ended December 31, 2014. For the year, on consolidated basis, the company reported operating loss was EUR 36,090,000 compared to income of EUR 1,499,000 a year ago. Income loss before taxes was EUR 35,165,000 compared to income of EUR 3,651,000 a year ago. Net loss was EUR 35,165,000 compared to income of EUR 5,846,000 a year ago. Investments in property, plant and equipment was EUR 146,000 compared to EUR 329,000 a year ago. Investments in intangible assets were EUR 50,000 compared to EUR 52,000 a year ago. Return on equity was negative 52.9% compared to 4.7% a year ago. For the year, on parent basis, revenue was EUR 7,278,000 compared to EUR 4,485,000 a year ago. Operating loss was EUR 278,000 compared to EUR 3,010,000 a year ago. Profit before extraordinary items, appropriations and taxes were EUR 5,090,000 compared to loss of EUR 509,000 a year ago. Net income was EUR 5,090,000 compared to loss of EUR 509,000 a year ago. Cash flow used in operating activities was EUR 229,000 compared to EUR 4,039,000 a year ago. Capital expenditure was EUR 39,000 compared to EUR 83,000 a year ago.

Biotie Therapies Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Biotie Therapies Corp. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net loss was EUR 32.4 million compared to net profit of EUR 1.7 million a year ago. Revenues were EUR 1.9 million against EUR 5.8 million a year ago. Cash out flows from operating activities of EUR 4.7 million against EUR 2.8 million a year ago. Loss per share was EUR 0.07. For the year, the company reported revenues were EUR 14.9 million against EUR 27.7 million a year ago. Cash out flow from operating activities was EUR 14.1 million against cash inflows from operating activities of 10.6 million a year ago. Loss per share was EUR 0.08 against earnings per share of EUR 0.01 a year ago.

Biotie Provides Portfolio Update on Tozadenant

Biotie announced further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease (PD). Biotie plans to conduct one Phase 3 study in 882 PD patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations) in which participants will be randomized in a double-blind manner to receive twice daily doses of 60mg or 120mg of tozadenant or placebo in addition to their standard anti-PD medications, for 24 weeks. The primary endpoint will be time spent in the "off" state in patients taking tozadenant as compared to placebo between baseline and week 24. Secondary endpoints will include "on" time without troublesome dyskinesia, the Unified Parkinson's Disease Rating Scale, Clinical Global Impression of Change and Patient Global Impression of Change. The placebo-controlled period will be followed by a 52 week open label treatment period to collect additional clinical safety data. The planned Phase 3 study is expected to start recruiting patients in the United States, Canada and selected European countries in the middle of 2015. Based on current estimates, top-line data is expected to be available by the end of 2018. Biotie has previously reported positive data from a 420-patient Phase 2b study evaluating tozadenant in PD patients experiencing levodopa related end-of-dose 'wearing-off'. Full data from this trial was published in Lancet Neurology in 20141. The trial met its primary endpoint of a highly significant decrease in "off" time vs. placebo, as well as demonstrating efficacy across multiple secondary endpoints. The Phase 3 protocol will largely replicate that of the Phase 2b study. Biotie expects that the published Phase 2b study will be considered the first of two pivotal studies required for registration for tozadenant in PD patients with end-of-dose 'wearing-off'. Biotie is considering financing options which may involve a capital raise to fully fund the tozadenant Phase 3 program to approval.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTH1V:FH €0.18 EUR +0.001

BTH1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTH1V.
View Industry Companies

Industry Analysis


Industry Average

Valuation BTH1V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIE THERAPIES OYJ, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at